Clinical Trial Update: Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating TQB2440 injected with Perjeta and trastuzumab plus docetaxel for early or locally advanced HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Perjeta (pertuzumab)
• TQB2440
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: UNKNOWN